Research programme: oral cancer therapeutics - Introgen/Colgate-Palmolive

Drug Profile

Research programme: oral cancer therapeutics - Introgen/Colgate-Palmolive

Latest Information Update: 18 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Introgen Therapeutics
  • Developer Colgate-Palmolive; Introgen Therapeutics
  • Class
  • Mechanism of Action Tumour suppressor gene transcription stimulants; Tumour suppressor protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top